Article Text

Download PDFPDF

G59 The international collaborative infantile spasms study (iciss) comparing hormonal therapies (prednisolone or tetracosactide depot) and vigabatrin versus hormonal therapies alone in the treatment of infantile spasms: early clinical outcome
  1. F O’Callaghan1,
  2. S Edwards2,3,
  3. E Hancock3,
  4. A Johnson4,
  5. C Kennedy5,
  6. A Lux6,
  7. M Mackay7,
  8. R Newton8,
  9. M Nolan9,
  10. D Rating10,
  11. B Schmitt11,
  12. C Verity12,
  13. J Osborne2,3
  1. 1Clinical Neurosciences, UCL, London, UK
  2. 2Department for Health, University of Bath, Bath, UK
  3. 3Children’s Centre, Royal United Hospital, Bath, UK
  4. 4MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
  5. 5Faculty of Medicine, University of Southampton, Southampton, UK
  6. 6Paediatric Neurology, Bristol Royal Hospital for Children, Bristol, UK
  7. 7Paediatric Neurology, Royal Children’s Hospital, Melbourne, Australia
  8. 8Paediatric Neurology, Royal Manchester Children’s Hospital, Manchester, UK
  9. 9Paediatric Neurology, Starship Children’s Hospital, Auckland, New Zealand
  10. 10Neuropaediatrics, University of Heidelberg, Heidelberg, Germany
  11. 11Neuropaediatrics, University Children’s Hospital, Zurich, Switzerland
  12. 12Paediatrics, Addenbrooke’s Hospital, Cambridge, UK


Infantile spasms (IS) are a serious epileptic encephalopathy that occur most commonly between 2 and 14 months. The spasms occur in association with hypsarrhythmia or similar on EEG. There is often coincident psychomotor arrest or regression. Between March 2007 and May 2014, infants with IS and a compatible EEG were enrolled in a multicenter treatment trial. Participating countries were the UK, Germany, Switzerland, Australia and New Zealand. Infants were randomised to receive either hormonal therapy and vigabatrin or hormonal therapy alone. A second stage randomization allowed hormonal treatment to be allocated as either prednisolone or tetracosactide depot. Minimum doses were: vigabatrin 100 mg/kg/day, prednisolone 40 mg per day, or IM tetracosactide depot 0.5 mg on alternate days. Hormonal treatment was continued for 2 weeks and then weaned over 2 weeks. Vigabatrin was continued for 3 months and then weaned over a month. The early primary outcome measure was cessation of spasms on and between days 14 and 42. Analysis is by intention to treat. 377 children were enrolled and early clinical outcome data will be available on 376 (1 case withdrew). 186 were allocated hormonal therapy and vigabatrin and 191 were allocated hormonal therapy alone. We will report on the primary clinical outcome and serious adverse clinical events. Developmental outcome at 18 months of age will be reported in a subsequent paper. To date this is by far the largest treatment study of infantile spasms ever undertaken.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.